RSS Feed Print
Case Study: IViG Keeps Alzheimer's at Bay for a Decade
Posted: Monday, July 23, 2012 2:47 PM
Joined: 12/6/2011
Posts: 3326

From Alzheimer's Daily News:

(Source: ABC News) - Jason Marder watched the inevitable decline of his younger brother, who died of Alzheimer's disease at the age of 50. Then, just after his 60th birthday, he too, began to exhibit subtle, early symptoms - forgetfulness and difficulty focusing on conversations.

The memory loss progressed, and in 2004, Marder got the dreaded diagnosis: Alzheimer's.


But today, eight years after his diagnosis, Marder isn't any worse off. He has shown no further memory loss and has remained stable.


The Marders credit intravenous immunoglobulin, or IViG, therapy and a clinical trial that is swirling in controversy this week after an announcement of study results by the Alzheimer's Association International Conference 2012 in Vancouver.


Some doctors hailed the therapy as "exciting," something that could potentially stabilize the disease, while others said the research is inconclusive and the study - with only 16 subjects - was too small.


"This drug saved his life," said Karin Marder. "He's independent. He gets on the subways, bikes up and down the Hudson River, gets to go out with friends. He goes to the senior center twice a week. He does creative writing."


For the past five years, Marder has been part of a clinical trial with Dr. Norman Relkin, director of the Memory Disorders Program at New York-Presbyterian/Weill Cornell Medical Center.


Relkin presented data that found,overall, that 11 study participants who received the immunotherapy Gammagard (IViG) for three full years showed improvements in cognition, memory, daily functioning and mood.


"We are seeing encouraging results," Relkin told And despite negative publicity, "I don't want people to give up hope for symptomatic treatment of the disease".


Go to full story: